Shopping Cart

Your shopping cart is currently empty

Rosuvastatin

Name: Rosuvastatin
Brand: TargetMol
SKU: T1676
Price: 40 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T1676Cas No. 287714-41-4

Alias ZD 4522

Rosuvastatin (ZD4522) is an inhibitor of HMG-CoA reductase (HMGCR) (IC50=11 nM), selective and competitive. Rosuvastatin has hypolipidemic and antiatherosclerotic effects.

Rosuvastatin

Copy Product Info

🥰Excellent

Purity: 99.95%

Catalog No. T1676Alias ZD 4522Cas No. 287714-41-4

Rosuvastatin (ZD4522) is an inhibitor of HMG-CoA reductase (HMGCR) (IC50=11 nM), selective and competitive. Rosuvastatin has hypolipidemic and antiatherosclerotic effects.

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$40	In Stock	In Stock
10 mg	$59	In Stock	In Stock
25 mg	$109	In Stock	In Stock
50 mg	$166	In Stock	In Stock
100 mg	$247	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$42	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.95%

Color:White to Yellow

Resource Download

COA LCMS HNMR

Product Introduction

Rosuvastatin AI Summary

Rosuvastatin exhibits potent bioactivity primarily as an inhibitor of HMG-CoA reductase, displaying extremely low IC50 values across various models, indicating strong inhibition of cholesterol synthesis. In rat hepatocytes, it has a highly potent IC50 of 0.23 nM, while in liver microsomes, it shows an IC50 of approximately 3.1 nM. Studies demonstrate its varying potency across different cell types, including less effective inhibition in rat L6 myocytes with an IC50 of 250.0 nM. It also exhibits substantial inhibition in acute cholesterol synthesis in mice and reduces LDL cholesterol levels in multiple animal models. Pharmacokinetic assessments reveal significant bioavailability challenges, with only 20% oral bioavailability and substantial metabolism in the liver and intestines. Additionally, the compound undergoes extensive plasma protein binding and clearance in humans. Although showing modest antimalarial, antiviral, and antiproliferative activities, it possesses notable liver toxicity risks, as evidenced by predictions and clinical trial observations. Rosuvastatin also interacts with various human and rat hepatic transporters, influencing drug uptake and clearance rates in hepatic systems. Further, it affects permeability and transport interactions in cellular assays, including drug uptake ratios in hepatic and Caco-2 cells. These combined properties suggest Rosuvastatin holds potential as a robust hypolipidemic agent but necessitates careful consideration of its pharmacokinetic and toxicity profiles..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Rosuvastatin (ZD4522) is an inhibitor of HMG-CoA reductase (HMGCR) (IC50=11 nM), selective and competitive. Rosuvastatin has hypolipidemic and antiatherosclerotic effects.
Targets&IC50	HMG-CoA:11 nM
In vitro	METHODS: Microglia cultures subDIV were treated with Rosuvastatin (1 µM) and LPS (20 ng/mL) for 24 h, and cell counts were measured by Bürker chamber. RESULTS: After the 24 h treatment period, Rosuvastatin significantly inhibited cell proliferation in unchallenged and LPS-challenged cultures by 47.8% and 68.9%, respectively. [1] METHODS: Nthy-ori 3-1 and B-CPAP cells were treated with Rosuvastatin (12.5-200 µM) for 48-72 h. Apoptosis was detected by TUNEL assay. RESULTS: The number of apoptotic cells increased in both Nthy ori 3-1 and B-CPAP cells after Rosuvastatin treatment. 12.5 µM concentration of Rosuvastatin treatment resulted in an increase in Apoptotic Index of Nthy ori 3-1 and B-CPAP cells after 48 h. The results were summarized as follows. [2]
In vivo	METHODS: To investigate the anti-atherosclerotic effects, Rosuvastatin (5 mg/kg) and candesartan (2.5 mg/kg) were administered by gavage to streptozotocin-induced diabetic Apoe-/- mice once daily for 20 weeks. RESULTS: In the absence of lipid-lowering effects, Rosuvastatin attenuated plaque area in diabetic mice.The anti-atherosclerotic effect of Rosuvastatin was comparable to that of candesartan. Dual therapy had similar beneficial effects, although it was not superior to monotherapy. [3]
Synonyms	ZD 4522

Chemical Properties

Molecular Weight	481.54
Formula	C₂₂H₂₈FN₃O₆S
Cas No.	287714-41-4
Smiles	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O
Relative Density.	1.368 g/cm3

Storage & Solubility Information

Storage

keep away from moisture,store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 1 mg/mL (2.08 mM), Sonication is recommended.

DMSO: 50 mg/mL (103.83 mM), Sonication is recommended.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.0767 mL	10.3834 mL	20.7667 mL	103.8335 mL

DMSO

	1mg	5mg	10mg	50mg
5 mM	0.4153 mL	2.0767 mL	4.1533 mL	20.7667 mL
10 mM	0.2077 mL	1.0383 mL	2.0767 mL	10.3834 mL
20 mM	0.1038 mL	0.5192 mL	1.0383 mL	5.1917 mL
50 mM	0.0415 mL	0.2077 mL	0.4153 mL	2.0767 mL
100 mM	0.0208 mL	0.1038 mL	0.2077 mL	1.0383 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Rosuvastatin

Rosuvastatin

Featured Recommendations

Batch Information

Resource Download

Product Introduction

Calculator

In Vivo Formulation Calculator (Clear solution)

Dose Conversion

Tech Support

Keywords